ANAB Key Statistics, Chart & Performance
The current stock price of ANAB is 50.64 USD. In the past month the price increased by 18.54%. In the past year, price increased by 251.24%.
ANAB Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to ANAB. When comparing the yearly performance of all stocks, ANAB is one of the better performing stocks in the market, outperforming 98.17% of all stocks.
ANAB Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ANAB. ANAB has a bad profitability rating. Also its financial health evaluation is rather negative.
ANAB Financial Highlights
Over the last trailing twelve months ANAB reported a non-GAAP Earnings per Share(EPS) of -2.82. The EPS increased by 53.62% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -23.97% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ANAB Forecast & Estimates
19 analysts have analysed ANAB and the average price target is 63.92 USD. This implies a price increase of 26.22% is expected in the next year compared to the current price of 50.64.
For the next year, analysts expect an EPS growth of 76.09% and a revenue growth 280.69% for ANAB
ANAB Ownership
ANAB Latest News, Press Relases and Analysis
ANAB Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.53 | 398.827B | ||
| AMGN | AMGEN INC | 15.8 | 182.324B | ||
| GILD | GILEAD SCIENCES INC | 16.2 | 177.765B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.47 | 118.135B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.65 | 79.79B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 48.6 | 46.476B | ||
| INSM | INSMED INC | N/A | 33.518B | ||
| NTRA | NATERA INC | N/A | 31.422B | ||
| BIIB | BIOGEN INC | 11.77 | 25.931B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.32 | 20.594B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ANAB
Company Profile
AnaptysBio, Inc. is a clinical stage biotechnology company. The company is headquartered in San Diego, California and currently employs 136 full-time employees. The company went IPO on 2017-01-26. The firm is focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. The Company’s lead program, Rosnilimab, is a depleter and agonist targeting PD-1+ T cells, is in a Phase IIb trial for the treatment of rheumatoid arthritis and in a Phase II trial for the treatment of ulcerative colitis. The Company’s pipeline also includes ANB033, a CD122 antagonist, and ANB101, a blood dendritic cell antigen 2 (BDCA2) modulator, in Phase I trials. The company has also discovered multiple therapeutic antibodies licensed to GSK in a financial collaboration for immuno-oncology, including a PD-1 antagonist (Jemperli (dostarlimab-gxly)) and a TIM-3 antagonist (cobolimab, GSK4069889). Rosnilimab is an IgG1 antibody that directly targets PD-1+ T cells, resulting in their depletion or agonism, impacting pathogenic drivers of autoimmune and inflammatory diseases.
Company Info
ANAPTYSBIO INC
10770 Wateridge Circle, Suite 210
San Diego CALIFORNIA 92121 US
CEO: Hamza Suria
Employees: 136
Phone: 18583626295
ANAPTYSBIO INC / ANAB FAQ
What does ANAB do?
AnaptysBio, Inc. is a clinical stage biotechnology company. The company is headquartered in San Diego, California and currently employs 136 full-time employees. The company went IPO on 2017-01-26. The firm is focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. The Company’s lead program, Rosnilimab, is a depleter and agonist targeting PD-1+ T cells, is in a Phase IIb trial for the treatment of rheumatoid arthritis and in a Phase II trial for the treatment of ulcerative colitis. The Company’s pipeline also includes ANB033, a CD122 antagonist, and ANB101, a blood dendritic cell antigen 2 (BDCA2) modulator, in Phase I trials. The company has also discovered multiple therapeutic antibodies licensed to GSK in a financial collaboration for immuno-oncology, including a PD-1 antagonist (Jemperli (dostarlimab-gxly)) and a TIM-3 antagonist (cobolimab, GSK4069889). Rosnilimab is an IgG1 antibody that directly targets PD-1+ T cells, resulting in their depletion or agonism, impacting pathogenic drivers of autoimmune and inflammatory diseases.
Can you provide the latest stock price for ANAPTYSBIO INC?
The current stock price of ANAB is 50.64 USD. The price decreased by -1.11% in the last trading session.
Does ANAB stock pay dividends?
ANAB does not pay a dividend.
What is the ChartMill rating of ANAPTYSBIO INC stock?
ANAB has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Is ANAPTYSBIO INC (ANAB) expected to grow?
The Revenue of ANAPTYSBIO INC (ANAB) is expected to grow by 280.69% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
When does ANAPTYSBIO INC (ANAB) report earnings?
ANAPTYSBIO INC (ANAB) will report earnings on 2026-02-25, after the market close.
Can you provide the ownership details for ANAB stock?
You can find the ownership structure of ANAPTYSBIO INC (ANAB) on the Ownership tab.